Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00392652
Other study ID # NCI-2009-00867
Secondary ID NCI-2009-00867CD
Status Completed
Phase Phase 1
First received October 25, 2006
Last updated December 28, 2016
Start date November 2006
Est. completion date October 2009

Study information

Verified date December 2016
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This randomized phase I trial is studying the side effects and best dose of diindolylmethane in healthy volunteers. Chemoprevention is the use of certain drugs or substances to keep cancer from forming, growing, or coming back. The use of diindolylmethane may keep cancer from forming. Collecting and storing samples of blood and urine from healthy volunteers to study in the laboratory may help doctors learn more about the way a person's body handles the drug.


Description:

PRIMARY OBJECTIVES:

I. Determine the effect of multiple daily dosing with nutritional-grade, absorption-enhanced diindolylmethane (BR-DIM) on the disposition of probe drugs metabolized by cytochrome P4501A2 (CYP1A2) and CYP3A4 in healthy volunteers.

SECONDARY OBJECTIVES:

I. Determine the effect of multiple daily doses of BR-DIM on estrogen metabolites in urine and on activities of CYP2C9, CYP2D6, and P-glycoprotein/OATP.

II. Determine the effect of a single dose of BR-DIM on the disposition of probe drugs that are metabolized or transported by CYP1A2, CYP2C9, CYP2D6, CYP3A4, and P-glycoprotein (P-go).

III. Determine the safety and tolerability of single and multiple daily doses of BR-DIM.

IV. Determine the pharmacokinetics of a single dose of BR-DIM and of the same dose after chronic daily dosing.

V. Determine the pharmacokinetics of a single dose of BR-DIM and of the same dose after chronic daily dosing.

TERTIARY OBJECTIVES:

I. To determine effects of BR-DIM on activities of glutathione-S-transferase (GST), a phase 2 enzyme, in lymphocytes.

OUTLINE: This is a randomized, double-blind study. Participants are stratified according to gender. Participants are randomized to 1 of 2 intervention arms.

Arm I: Participants receive low-dose oral diindolylmethane (BR-DIM) twice daily for 4 weeks.

Arm II: Participants receive high-dose oral BR-DIM twice daily for 4 weeks.

In both arms, participants receive an oral probe-drug cocktail comprising caffeine (CYP1A2), dextromethorphan (CYP2D6), buspirone (CYP3A4), losartan (CYP2C9), and fexofenadine (P-glycoprotein) before randomization and after the first and last dose of BR-DIM.

Blood and urine are collected periodically for pharmacokinetic profiles of BR-DIM and probe drugs.

After completion of study intervention, participants are followed at 1 week.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date October 2009
Est. primary completion date October 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 70 Years
Eligibility Criteria:

- Healthy men and women

- Nonsmoker confirmed by urine cotinine test

- No active malignancy

- Life expectancy >= 12 months

- Hemoglobin > 10 g/dL

- Absolute granulocyte count > 1,500/mm^3

- Creatinine < 2.0 mg/dL

- Albumin > 3.0 g/dL

- Bilirubin < 1.8 mg/dL

- AST and ALT < 110 U/L

- Alkaline phosphatase < 300 U/L

- Body mass index =< 30

- Not pregnant or nursing

- Negative pregnancy test

- Fertile participants must use effective nonhormonal contraception

- No acute, unstable, chronic, or recurring medical conditions

- No strict vegetarians or consumption of > 3 medium servings (1/2 cup each) of cruciferous vegetables per week

- Participants who have stopped eating cruciferous vegetables within the past 2 weeks and agree to refrain from eating them for the duration of the study are eligible

- Cruciferous vegetables include broccoli, cabbage (including coleslaw), cauliflower, bok-choy, brussels sprouts, collards, kale, kohlrabi, mustard greens, rutabaga, turnip, and watercress

- No serious drug allergies or other serious intolerance or allergies

- Mild seasonal allergies allowed

- No chronic conditions, including headaches, dysphoria, fatigue, dizziness, blurred vision, insomnia, rhinorrhea, nausea, vomiting, abdominal pain, diarrhea, constipation, menopausal hot flashes/night sweats, or clinically significant premenstrual syndrome

- No serious acute or chronic illness

- No requirement for chronic drug therapy

- No alcohol ingestion within 48 hours of study treatment

- No investigational drugs within the past 3 months

- No prior chemotherapy

- No concurrent regular medications or hormones

- No recent change in medications or dosage of medications

- No concurrent regular supplements or vitamins

- No concurrent over-the-counter medications

- No concurrent grapefruit or its juice

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
oral microencapsulated diindolylmethane
Given PO

Locations

Country Name City State
United States University of Kansas Medical Center Kansas City Kansas

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effect of diindolylmethane (BR-DIM) on activities of CYP3A4 and CYP1A2 Descriptive statistics will be calculated on all variables of interest: frequencies and percentages will be used to summarize categorical variables and medians, and ranges will summarize quantitative variables. Paired t-tests will be used to compare enzyme levels post-pre at each dose. Analysis of covariance will be used to determine if there is a dose effect on enzyme levels, using the baseline values as a covariate. If there is no dose effect, the seven subjects at each dose will be pooled which will provide an increase power to detect meaningful changes in enzyme levels. Up to 1 week No
Primary Grade 2 or higher toxicities, graded using NCI CTC version 2.0 A one-sided binomial test will be used. Descriptive statistics will be calculated on all variables of interest: frequencies and percentages will be used to summarize categorical variables and medians, and ranges will summarize quantitative variables. Up to 1 week Yes
Primary Steady-state pharmacokinetic parameters such as half-life, Cmax, Tmax, and AUC Pharmacokinetic parameters between pre- and post-menopausal women will be compared using the Wilcoxon rank-sum test. Up to 1 week No
Secondary Drug metabolizing enzyme values (CYP2C9, CYP2D6, P-glycoprotein/OATP, and glutathione-S-transferase) The probe drug values for the first three enzymes for the baseline (placebo) values and the first-dose BR-DIM values compared to assess inhibitory possible interactions, and between baseline and last-dose BR-DIM values to assess the possibility of either inhibitory or inductive events. Measurements of lymphocyte cytosolic GST activities will compare baseline to last-dose BR-DIM values, and thus assess the possibility of either inhibitory or inductive events. Since we anticipate skewed data, we will compare the values listed above using nonparametric Wilcoxon sign rank tests. Up to 1 week No
Secondary 2/16 alpha OHE ratio in urine A one-way repeated measures analysis of variance will be used to compare this ratio across treatment periods (baseline, one month on BR-DIM, one month after stopping BR-DIM). We will summarize 2/16 alpha OHE ratio at each dose by means and standard deviations. If there is a large degree of skewness the median and range will be utilized as summary measures and Friedman's test utilized to assess the effect of BR-DIM on metabolites of estrogen in urine. Up to 1 month No
See also
  Status Clinical Trial Phase
Completed NCT01950403 - Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers Phase 1
Terminated NCT01336387 - Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers Phase 1
Terminated NCT01561989 - Cholecalciferol and Flu Vaccine in Treating Healthy Participants N/A
Completed NCT01140646 - Evaluation of SAMe for Hot Flashes Phase 2
Completed NCT00892515 - Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer N/A
Completed NCT00365209 - Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci) Phase 2
Completed NCT00450957 - Lycopene in Healthy Male Participants Phase 1
Recruiting NCT04445532 - Hepatobiliary Tumors Tissue Samples Acquisition
Completed NCT02100254 - Narrative or Fact-Based Videos in Increasing Colorectal Cancer Screenings in African American Communities N/A
Completed NCT02129517 - Web-Based Tailored Educational Program in Improving Nurse Communication With Patients About Clinical Trials N/A
Terminated NCT01755208 - Light-Scattering Spectroscopy for Detection of Breast Cancer N/A
Completed NCT00499460 - Effects of Garlic Supplements on Opioids in Healthy Volunteers Phase 4
Completed NCT01077453 - Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer Phase 1
Completed NCT00478309 - Genetic Epidemiology Risk Assessment Program or Usual Care in Colorectal Cancer Screening for Healthy Participants N/A
Completed NCT01370889 - Resveratrol in Postmenopausal Women With High Body Mass Index Phase 1
Completed NCT00896207 - Studying Different Formulations of SR13668 in Healthy Volunteers Phase 1
Completed NCT00679094 - Bowman-Birk Inhibitor Concentrate in Healthy Men Phase 1
Terminated NCT02154984 - Time Restricted Diet in Obese or Overweight Pre or Postmenopausal Participants N/A
Completed NCT00489372 - Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients Phase 1
Completed NCT00513916 - Effect of Dietary Soy on Estrogens in Breast Fluid, Blood, and Urine Samples From Healthy Women Phase 3